Mabvax Therapeutics Holdings Inc., of San Diego, priced a public offering o $8.625 million of common stock and series F preferred stock at $4.81 per share of common stock or series F preferred stock. Laidlaw & Co. (UK) Ltd. acted as the sole book-running manager. Underwriters have a 45-day option to purchase up to an aggregate of 169,179 additional shares (with additional class A warrants and class B warrants) solely to cover overallotments.